Kurt Haggstrom, Synchron | theCUBE + NYSE Wired MedTech Unplugged Series
Show Notes
In this episode of MedTech Unplugged, Kurt Haggstrom, Chief Commercial Officer at Synchron, discusses the innovative approach the company is taking with its brain-computer interface (BCI). Unlike traditional invasive methods, Synchron’s BCI is implanted via the bloodstream using a device called Stentrode, which aims to restore digital control for patients with severe motor impairments. Haggstrom explains how this technology allows users with conditions such as paralysis and ALS to control smart devices using their thoughts, highlighting the importance of autonomy and social connection for these individuals. The episode delves into Synchron's plans for clinical trials, safety data, partnerships with companies like Apple and NVIDIA, and the potential impact of AI on the decoding of neural signals. Haggstrom also touches on regulatory processes, reimbursement strategies, and the future of accessible healthcare solutions for patients.
Key Topics Covered:- Overview of Synchron's brain-computer interface (BCI) technology
- Innovative delivery method via bloodstream using the Stentrode implant
- Patient autonomy and restoring digital control for individuals with motor impairments
- Upcoming clinical trials and safety data for the BCI
- Collaborations with Apple’s iOS ecosystem and NVIDIA for enhanced application integration
- Regulatory clarity and navigating the FDA approval process
- Strategies for reimbursement and ensuring broad access to the technology
- The role of AI in improving neural signal decoding and device control